Company: SINT
Filing Date: 2025-10-03
Form Type: 424B5
Source: 0001493152-25-016902
Chunk: 8

Company: Sintx Technologies, Inc.
Filing Date: 2025-10-03
Form: 424B5
Chunk 8
---
 exercise of outstanding warrants;                                                       |
| ● | 7,385                                                                                                                            
 shares of our common stock issuable upon the conversion of 19 shares of series B convertible preferred stock outstanding;        |
| ● | 2                                                                                                                                
 shares of our common stock issuable upon the conversion of 50 shares of series C convertible preferred stock outstanding; and    |
| ● | 60                                                                                                                               
 shares of common stock reserved for issuance upon conversion of 180 shares of the Series D Preferred Stock outstanding.          |

Unless otherwise indicated, the information in this prospectus supplement, including the number of shares outstanding after this offering, does not reflect (i) any issuance, exercise, vesting, expiration, or forfeiture of any additional equity awards under our incentive plans that occurred after September 30, 2025 or (ii) the effect of the “full-ratchet” anti-dilution adjustment of the conversion price of our outstanding Series B Convertible Preferred Stock and the exercise price of our outstanding warrants issued in our October 2022 rights offering. Except as otherwise indicated, all information in this prospectus supplement assumes no exercise of outstanding stock options or warrants described above.

| S-2 |

<div align='center'>RISK FACTORS</div>

Investing in our securities involves a high degree of risk. You should carefully review the risks and uncertainties described below and under the section titled “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K we file after the date of this prospectus supplement and the accompanying prospectus, and all other information contained or incorporated by reference into this prospectus supplement and the accompanying prospectus, as updated by our subsequent filings under the Exchange Act, before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.

Risks Relating to this Offering

We have outstanding shares of convertible preferred stock and Common Stock purchase warrants which contain anti-dilution protections, which may cause significant dilution to our stockholders.

As of September 30, 2025, we had outstanding 19 shares of Series B convertible preferred stock convertible into an aggregate of 7,385 shares of Common Stock at a conversion price of $4.20 per share and warrants issued in October 2022 that are exercisable for an aggregate of 3,084 shares of Common Stock (the “October 2022 Warrants”). The October